CAMBRIDGE, Mass. - Wave Life Sciences Ltd. (NASDAQ:WVE) announced that its application for court approval of a redomiciliation from Singapore to the United States will be heard by the High Court of the Republic of Singapore on Monday at 2:30 pm Singapore Time.

The biotechnology company filed its application with the Singapore Court on July 1 in HC/SUM 2058/2026 in HC/OA 434/2026, according to a press release statement. The hearing will take place at Chamber 2A of the Supreme Court of Singapore at 1 Supreme Court Lane.

The redomiciliation is being implemented through a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore. The company previously obtained the required shareholder approval for the proposed redomiciliation.

The Singapore Court has set specific deadlines for responses to the application. Any affidavits in response must be submitted by 4:00 pm Singapore Time on Wednesday, while written submissions and bundles of authorities must be filed by 4:00 pm Singapore Time on Friday.

Wave Life Sciences stated that copies of the materials filed with the application and related directions from the Singapore Court will be available in the Corporate Governance section of its Investor Relations website.The company’s stock has shown recent volatility, gaining 8.78% over the past week while declining 59% over the past six months to its current price of $6.38. According to InvestingPro analysis, Wave holds more cash than debt on its balance sheet, a positive indicator as it navigates the redomiciliation process. Analysts remain optimistic, with price targets ranging from $12 to $43, and InvestingPro subscribers have access to 10 additional exclusive tips about the company’s financial health and prospects.

The company is a clinical-stage biotechnology firm focused on RNA medicines. Its pipeline includes programs in obesity, alpha-1 antitrypsin deficiency, liver disease, Duchenne muscular dystrophy and Huntington’s disease. Wave Life Sciences is headquartered in Cambridge, Massachusetts.

In other recent news, Wave Life Sciences has initiated the Phase 2a portion of the INLIGHT trial for its investigational treatment, WVE-007, targeting obesity. This placebo-controlled study will assess various health metrics over a 12-month period in participants from the U.S. and Europe. Concurrently, Wells Fargo raised its price target for Wave Life Sciences to $14, citing favorable data from the WVE-007 program related to alpha-1 antitrypsin deficiency (AATD). However, H.C. Wainwright lowered its price target to $13, referencing the WVE-006 ATS 2026 readout, which showed lower results compared to competitors. Cantor Fitzgerald maintained an Overweight rating and a $13 price target for the company, commenting on the stability of the WVE-006 program. Additionally, Wave Life Sciences reported updated data from its RestorAATion-2 trial for WVE-006, an RNA editing treatment for AATD, involving 24 participants across different dose cohorts. These developments reflect ongoing efforts and varying analyst perspectives on the company’s initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.